Literature DB >> 11478735

5-Aminolevulinic acid inhibits [3H]muscimol binding to human and rat brain synaptic membranes.

T Emanuelli1, F W Pagel, L B Alves, A Regner, D O Souza.   

Abstract

The interaction of 5-aminolevulinic acid (ALA) with GABA(A) receptors has been proposed to underlie the neurological dysfunctions of ALA-accumulating disorders, such as acute intermittent porphyria. The effects of ALA on [3H]muscimol binding to human and rat cerebral cortical membranes were compared. ALA (0.1-10 mM) significantly inhibited the binding of [3H]muscimol (12 nM), with a similar potency in rat and human membranes (IC50 = 199 vs. 228 microM, respectively). Kinetical analysis revealed that ALA (1 mM) significantly increased the Kd and decreased the Bmax of [3H]muscimol to both rat (100 and 50%, respectively) and human (200 and 40%, respectively) membranes, indicating a mixed-type inhibition. The similarity in the potency and mechanism of the ALA-induced inhibition of muscimol binding in rat and human membranes indicate that rat studies are useful to evaluate the neurotoxic properties of ALA towards the human GABAergic system, and may help to understand the pathophysiology of porphyria.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11478735     DOI: 10.1023/a:1011034409814

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  19 in total

1.  The interaction of porphyrin precursors with GABA receptors in the isolated frog spinal cord.

Authors:  R A Nicoll
Journal:  Life Sci       Date:  1976-08-15       Impact factor: 5.037

2.  Delta-aminolaevulinic acid is a potent agonist for GABA autoreceptors.

Authors:  M J Brennan; R C Cantrill
Journal:  Nature       Date:  1979-08-09       Impact factor: 49.962

3.  delta-Aminolevulinic acid: influences on synaptic GABA receptor binding may explain CNS symptoms of porphyria.

Authors:  W E Müller; S H Snyder
Journal:  Ann Neurol       Date:  1977-10       Impact factor: 10.422

Review 4.  An update on GABAA receptors.

Authors:  A K Mehta; M K Ticku
Journal:  Brain Res Brain Res Rev       Date:  1999-04

5.  Effect of delta-aminolaevulinic acid on GABA receptor binding in synaptic plasma membranes.

Authors:  M J Brennan; R C Cantrill; S Kramer
Journal:  Int J Biochem       Date:  1980

6.  Intrastriatal administration of 5-aminolevulinic acid induces convulsions and body asymmetry through glutamatergic mechanisms.

Authors:  T Emanuelli; C A Prauchner; J Dacanal; A Zeni; E C Reis; C F de Mello; D O de Souza
Journal:  Brain Res       Date:  2000-06-16       Impact factor: 3.252

7.  Differential expression of gamma-aminobutyric acidA receptor subunits.

Authors:  K M Garrett; N Saito; R S Duman; M S Abel; R A Ashton; S Fujimori; B Beer; J F Tallman; M P Vitek; A J Blume
Journal:  Mol Pharmacol       Date:  1990-05       Impact factor: 4.436

8.  The effect of porphyrin precursors on monosynaptic reflex activity in the isolated hemisected frog spinal cord.

Authors:  J M Loots; D M Becker; B J Meyer; N Goldstuck; S Kramer
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

9.  Gamma-aminobutyric acid binding to receptor sites in the rat central nervous system.

Authors:  S R Zukin; A B Young; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1974-12       Impact factor: 11.205

10.  A comparative study of the effects of delta-aminolaevulinic acid and the GABAA agonist, muscimol, in rat jejunal preparations.

Authors:  M G Cutler; J M Turner; M R Moore
Journal:  Pharmacol Toxicol       Date:  1991-07
View more
  3 in total

Review 1.  Porphyric Neuropathy: Pathophysiology, Diagnosis, and Updated Management.

Authors:  Mohamed Kazamel; Robert J Desnick; John G Quigley
Journal:  Curr Neurol Neurosci Rep       Date:  2020-10-07       Impact factor: 5.081

Review 2.  Fetal environment and schizophrenia.

Authors:  Mark G A Opler; Ezra S Susser
Journal:  Environ Health Perspect       Date:  2005-09       Impact factor: 9.031

3.  Porphyria: What Is It and Who Should Be Evaluated?

Authors:  Yonatan Edel; Rivka Mamet
Journal:  Rambam Maimonides Med J       Date:  2018-04-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.